International Journal of Radiation Oncology*Biology*Physics
Clinical InvestigationPatterns of Failure in Patients With Double Hit or Double Expressor Lymphomas: Implications for Radiation Therapy
Introduction
Standard immunochemotherapy of rituxan, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for diffuse large B-cell lymphoma (DLBCL) in unselected patients produces 6-year progression-free survival (PFS) in excess of 80% 1, 2. However, up to one-fourth of DLBCL harbor MYC and BLC2 or BCL6 gene rearrangements or protein overexpression, known as double-hit lymphomas (DHL) or double-expressor lymphomas (DEL), respectively, and are associated with significantly worse prognosis and response to traditional immunochemotherapy 3, 4, 5, 6. Although alternative intensified regimens have been associated with improved outcomes in nonrandomized experiences, the optimal therapy for DHL/DEL remains unclear 7, 8.
Similarly, whereas the role of consolidative radiation therapy is well delineated for limited stage disease and for bulky, partially responding, or special extranodal sites such as skeletal involvement 9, 10, 11, 12, 13, its effect in DHL/DEL specifically remains undefined. Descriptive studies have associated DHL/DEL with a predilection for extranodal and advanced stage presentation, and also with a poor response to immunochemotherapy and dismal salvage outcomes upon relapse 14, 15. This set of features thus may be suspected to alter or even obviate the traditional benefit of consolidative radiation therapy because of the competing risk of relapse at nonirradiated sites.
This study sought to detail the patterns of failure of DHL/DEL after immunochemotherapy and to analyze the implications for the role of radiation therapy for traditional indications in DLBCL.
Section snippets
Patient cohort
After institutional review board approval, a retrospective review was conducted on 275 cases of DLBCL diagnosed from 2011 to 2015 at 2 hospital systems within the same institution. DHL status was determined by fluorescence in-situ hybridization (FISH) for classic rearrangements in MYC and BCL-2 or BCL-6. DEL status was determined by immunohistochemistry (IHC) showing protein overexpression of MYC (≥40%) and BCL-2 (≥50%), in concordance with most prior analyses on DEL 16, 17 and the most recent
Analyses
Primary refractory disease was defined as progression or Lugano 4 to 5 (19) response on 18F-FDG positron emission tomography (PET) within 90 days of the completion of systemic or radiation therapy, if delivered. Complete response to chemotherapy was defined as achievement of a Lugano 1 to 3 response at end of therapy PET. Pattern of recurrence was delineated as at initially involved sites or at other (distant) sites, based on clinical or radiographic progression. Estimates of rates of local
Patient characteristics and treatments
Our inclusion criteria yielded 53 patients with DHL/DEL, including 32 with DHL, 10 with DEL, 2 triple expressors, and 9 triple rearranged patients. Corresponding to a change from on-request to reflexive testing for DHL status by FISH in 2014, the yield for DHL/DEL among DLBCL diagnoses increased from 15% (24/161 cases) to 25% (29/114) (Fisher's exact test P = .04) during the study period. The median follow-up time was 10 months. A total of 6 (11%) patients were stage I, 8 (15%) were stage II, 7
Patterns of Failure
Among those patients with complete response to chemotherapy, 11/38 (crude rate 29%) subsequently experienced relapse, as detailed in Table 2. Nine of these relapses were in patients with advanced disease at presentation: 6 with extranodal involvement, 2 with pulmonary involvement, 2 with more than 1 extranodal site, and 1 with only bone marrow involvement. The pattern of failure was at initially involved site(s) of disease in 6/11 (55%) of patients, of which 4 (36%) were isolated initial site
Prognostic Factor Analysis
Given the strong contribution of initially involved sites to relapse pattern and the potential implication on decision making for radiation therapy, we assessed for factors associated with recurrence, specifically recurrence at initially involved sites, in those patients achieving complete response to chemotherapy. We excluded primary refractory patients from this analysis because they had already experienced progression and did not inform decision making regarding consolidative radiation
Discussion
DHL/DEL are separate entities from traditional DLBCL, with significantly worse response to traditional immunochemotherapy and higher rates of presentation with advanced and extranodal disease 3, 4, 5, 6. Owing to the presumed competing risk of relapse at multifocal sites and increasing use of intensified immunochemotherapy, the role of consolidative radiation therapy in DHL/DEL remains unclear. In this single-institution retrospective study, we sought to determine the patterns of failure of DHL
References (21)
- et al.
CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group
Lancet Oncol
(2011) - et al.
Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: A randomised controlled trial (RICOVER-60)
Lancet Oncol
(2008) - et al.
MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: A GELA/LYSA study
Blood
(2015) - et al.
MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: A report from The International DLBCL Rituximab-CHOP Consortium Program
Blood
(2013) - et al.
Preliminary report of a multicenter prospective phase II study of DA-EPOCH-R in MYC-rearranged aggressive B-cell lymphoma
Blood
(2014) - et al.
Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: An exploratory analysis of the MabThera International Trial Group (MInT) study
Lancet Oncol
(2008) - et al.
Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: A multicenter retrospective analysis
Blood
(2014) - et al.
The 2016 revision of the World Health Organization classification of lymphoid neoplasms
Blood
(2016) - et al.
Modern radiation therapy for nodal non-Hodgkin lymphoma-target definition and dose guidelines from the International Lymphoma Radiation Oncology Group
Int J Radiat Oncol Biol Phys
(2014) - et al.
Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone
J Clin Oncol
(2012)
Cited by (7)
Radiation Therapy for Relapsed or Refractory Diffuse Large B-Cell Lymphoma: What Is the Right Regimen for Palliation?
2022, Advances in Radiation OncologyCitation Excerpt :For instance, a study of 25 patients with r/rDLBCL treated with palliative-intent low-dose RT (4 Gy in 2 fractions) found that bulky disease (>5 cm) was associated with inferior responses to RT.21 In contrast to the findings from our study, GCB cell of origin was associated with improved response rates. Whether higher palliative doses may be necessary for bulky disease or lymphomas with particular immunophenotypic or genetic features remains to be characterized.22-25 A larger multi-institutional review is currently underway to further investigate the association between gene rearrangements or overexpression and radiosensitivity.
Palliative Radiotherapy for Diffuse Large B-cell Lymphoma
2021, Clinical Lymphoma, Myeloma and LeukemiaCitation Excerpt :Similar to the previously mentioned studies, the median survival for this patient cohort was 7.1 months.23 Whether higher palliative doses may be necessary for lymphomas with particular immunophenotypic or genetic features (ie, ABC or germinal center B‐cell cell of origin; double/triple hit DLBCL with MYC + BCL2 or MYC + BCL6 chromosomal rearrangements or MYC + BCL2 + BCL6 chromosomal rearrangements, or double expressor DLBCL with overexpression of MYC + BCL2 or MYC + BCL6 by immunohistochemistry) remains to be characterized.24–27 The need for higher doses and more protracted regimens must be balanced with the patient's prognosis, performance status, quality of life, and personal wishes.
Impact of Double- or Triple-Hit Pathology on Rates and Durability of Radiation Therapy Response Among Patients With Relapsed or Refractory Large B-Cell Lymphoma
2020, Practical Radiation OncologyCitation Excerpt :To our knowledge, this is the first study assessing whether RT efficacy in the R/R setting is altered by DHL/THL status. Despite the chemorefractory nature of DHL/THL, recent retrospective studies31,32 have shown improved locoregional control in patients with DHL/THL that underwent consolidative RT after induction immunochemotherapy compared with patients who received chemotherapy alone. These studies suggest efficacy of RT in those patients with chemosensitive disease.
Perspectives on chemotherapy for the management of double-hit lymphoma
2020, Expert Opinion on PharmacotherapyCurrent perspectives on the treatment of double hit lymphoma
2019, Expert Review of HematologyNew tools of the trade: parsing out the role of radiotherapy for early-stage diffuse large B-cell lymphoma
2019, Leukemia and Lymphoma
Conflict of interest: none.